Search research articles
Contact Us
Filters
Showing results (431-440 of 564) with videos related to
Page
of 57
Sort By:
European Urology
|
April 21, 2024
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study
Fred Saad, Maha H A Hussain, Bertrand Tombal, et al.
World Journal of Urology
|
June 26, 2016
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer
M N Pham, A B Apolo, M De Santis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2023
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial
Maha Hussain, Bertrand Tombal, Fred Saad, et al.
Urologic Oncology
|
August 22, 2025
Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapy
C N Sternberg, P Squifflet, E D Saad, et al.
The Oncologist
|
March 5, 2026
Molecular Landscape of Prostate Cancers with Clival Metastases
Pornlada Likasitwatanakul, Steven M Blinka, Jabra G Zarka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2009
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial
Cora N Sternberg, Daniel P Petrylak, Oliver Sartor, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 20, 2024
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes
Y Loriot, D P Petrylak, A Rezazadeh Kalebasty, et al.
BJU International
|
June 30, 2018
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme
Ugo De Giorgi, Giacomo Cartenì, Diana Giannarelli, et al.
Oncology
|
January 17, 2015
Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial
Cora N Sternberg, Fabio Calabrò, Sergio Bracarda, et al.
Future Oncology (London, England)
|
April 29, 2024
A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer
Yohann Loriot, Arash Rezazadeh Kalebasty, Aude Fléchon, et al.
Page
of 57
Search research articles
Search
Showing results (431-440 of 564) with videos related to
Sort By:
Page
of 57
European Urology
|
April 21, 2024
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study
Fred Saad, Maha H A Hussain, Bertrand Tombal, et al.
World Journal of Urology
|
June 26, 2016
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer
M N Pham, A B Apolo, M De Santis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2023
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial
Maha Hussain, Bertrand Tombal, Fred Saad, et al.
Urologic Oncology
|
August 22, 2025
Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapy
C N Sternberg, P Squifflet, E D Saad, et al.
The Oncologist
|
March 5, 2026
Molecular Landscape of Prostate Cancers with Clival Metastases
Pornlada Likasitwatanakul, Steven M Blinka, Jabra G Zarka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2009
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial
Cora N Sternberg, Daniel P Petrylak, Oliver Sartor, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 20, 2024
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes
Y Loriot, D P Petrylak, A Rezazadeh Kalebasty, et al.
BJU International
|
June 30, 2018
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme
Ugo De Giorgi, Giacomo Cartenì, Diana Giannarelli, et al.
Oncology
|
January 17, 2015
Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial
Cora N Sternberg, Fabio Calabrò, Sergio Bracarda, et al.
Future Oncology (London, England)
|
April 29, 2024
A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer
Yohann Loriot, Arash Rezazadeh Kalebasty, Aude Fléchon, et al.
Page
of 57